TBPH Rasio cepet Theravance Biopharma

Theravance Biopharma (TBPH) generates revenue from the sale of gastrointestinal and respiratory therapies, receiving payments under licensing agreements. Meanwhile, the company delegates distribution and mass production to external contractors, maintaining internal control only over R&D. The environmental footprint is minimal due to the outsourcers' compliance with international chemical standards. This market valuation on GURU.Markets confirms these data, reaching the level of 13.39.

The quick ratio measures a company's ability to instantaneously settle short-term obligations by excluding low-liquidity inventories from the calculation and accounting only for cash and accounts receivable. By analyzing the quick ratio, an investor assesses the financial stability of Theravance Biopharma (TBPH), where the stability of cash flows from Yupelri royalties plays a critical role in funding operational activities and the development of new therapies.